Good
Mostly Aligned
Patient Risk:
Low
Summary
Mostly aligned with the label. Several claims about cramps are not supported or are unsupported by the specified label sections; a subset of statements about management is supported.
Category Scores
Accurate Statements
A doctor may adjust Lipitor dosage if muscle cramps occur.
6.1 Skeletal Muscle
A doctor may recommend alternative medications if muscle cramps occur.
6.1 Skeletal Muscle
Patients experiencing side effects while taking Lipitor should talk to their doctor.
6.1 Skeletal Muscle; 5.1 Skeletal Muscle
Your doctor may be able to adjust your dosage or recommend alternative medications.
6.1 Skeletal Muscle
It's essential to talk to your doctor about any side effects you experience while taking Lipitor.
6.1 Skeletal Muscle; 17.1 Muscle Pain
It's essential to talk to your doctor before taking any new medications, including supplements.
6.1 Skeletal Muscle; 17.1 Muscle Pain
Unsupported Statements
Lipitor is atorvastatin.
Not explicitly asserted as Lipitor = atorvastatin within the labeled sections provided.
Muscle cramps are a common side effect of Lipitor.
Label does not define cramps as a clearly labeled common adverse reaction with explicit frequency.
According to the FDA's Adverse Event Reporting System (FAERS), muscle cramps are one of the most common side effects reported by Lipitor users.
Postmarketing Experience lists adverse reactions but does not quantify FAERS frequency or rank.
A study published in the Journal of Clinical Lipidology found that muscle cramps were reported by 2.4% of Lipitor users.
Labeling does not cite this external study or percentage.
Muscle cramps were reported by 2.4% of Lipitor users, making it one of the top 10 most common side effects of the medication.
Not stated in the label; no top-10 ranking provided.
The exact mechanism by which Lipitor causes muscle cramps is not fully understood.
Label describes mechanism of action but does not state lack of full understanding.
One theory is that Lipitor can cause changes in the body's muscle metabolism, leading to muscle cramps.
Label does not present speculative theories as established explanations.
Another theory is that the medication can cause changes in the body's electrolyte balance, leading to muscle cramps.
Label does not present electrolyte-based theories as established mechanisms.
According to a study in the Journal of Sports Science and Medicine, up to 60% of athletes report muscle cramps during exercise.
Labeling does not cite external prevalence studies about athletes unrelated to Lipitor exposure.
Lipitor users were more likely to experience muscle cramps during exercise than non-users.
Label does not quantify differential risk during exercise vs. non-use.
Dehydration is a common cause of muscle cramps.
Not a labeled Lipitor-specific claim in the provided sections.
Staying hydrated can help prevent muscle cramps.
Not a labeled Lipitor-specific claim.
Foods rich in electrolytes can help maintain electrolyte balance.
Not a labeled Lipitor-specific claim.
Maintaining electrolyte balance can help prevent muscle cramps.
Not a labeled Lipitor-specific claim.
Warm up and cool down exercises can help prevent muscle cramps.
Not a labeled Lipitor-specific claim.
Regular stretching can help improve flexibility and reduce the risk of muscle cramps.
Not a labeled Lipitor-specific claim.
Muscle cramps are generally not a serious side effect of Lipitor.
Label does not state that cramps are universally not serious; the nuance of seriousness is not explicitly stated.
Muscle cramps can be uncomfortable and affect quality of life.
Not explicitly described in label as a quality-of-life impact.
Contradictions
Low
AI Statement
Muscle cramps are generally not a serious side effect of Lipitor.
Label Reference
6.1 Skeletal Muscle; 5.1 Skeletal Muscle
Important Omissions
Rhabdomyolysis risk with CK elevations and renal impairment; liver enzyme elevations; interactions with cyclosporine, strong CYP3A4 inhibitors, and other drugs; postmarketing hepatotoxicity and other events.
Importance:
High
Use in pregnancy/lactation, pediatric use, elderly considerations, and broader special populations.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Most claims concern management of common adverse experiences; they do not introduce new high-risk signals beyond what is in the label. Key risks like rhabdomyolysis and liver enzyme elevations exist in the label but are not emphasized in the claims.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Suggested Improvement